Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06450171
Other study ID # 24-070
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 2024
Est. completion date January 31, 2028

Study information

Verified date June 2024
Source Dana-Farber Cancer Institute
Contact Elizabeth ODonnell, MD
Phone 587-215-2361
Email elizabeth_odonnell@dfci.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to evaluate the possible benefits and harms of screening with an investigational blood test designed to detect many types of cancer early. The name of the screening blood test being studied is: -GRAIL Galleri test


Description:

This is a prospective, interventional study to assess the use of the GRAIL's Galleri multi-cancer early detection (MCED) Test, an investigational blood test designed to detect many types of cancer, for participants that are considered at slightly higher than average risk of developing certain types of cancers. The test looks for small pieces of genetic material called deoxyribonucleic acid (DNA) in the blood that may indicate the presence of cancer. The research study procedures include screening for eligibility, blood tests, questionnaires, and clinic visits. Participation in this research study is expected to last up to 3 years. It is expected that about 1,000 people will take part in this research study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1000
Est. completion date January 31, 2028
Est. primary completion date January 31, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 22 Years and older
Eligibility Inclusion Criteria Group 1- Cancer Predisposition Syndrome: - Age >22 for patients with TP53 germline pathogenic variants, age >35 for all other variants in cancer predisposing genes - Germline genetic testing revealed pathogenic germline variants in cancer predisposing genes (list of genes typically tested listed in pre-screening document) - Individuals with a clinically based diagnosis of a Cancer Predisposition Syndrome (examples, neurofibromatosis, Fanconi Anemia, Ataxia-Telangiectasia) Inclusion Criteria Group 2 - Familial Risk: - Age >45 - Adults with family history suggestive of elevated cancer risk as defined by any the criteria below, who do not fall into Group 1: - >1 first or second degree relative on same side of the family with: - Breast, colon, gastric, endometrial, kidney cancer at or before age 50 - Triple negative breast cancer (any age) - Male breast cancer (any age) - Ovarian, pancreatic, sarcoma cancer (any age) - Neuroendocrine cancer or tumors (any age) - Metastatic prostate cancer (any age) - Multiple primary cancers (example bilateral breast cancer) - >2 first or second degree relative on same side of the family (any combination is acceptable) with breast or prostate cancer at any age Exclusion Criteria: - Individuals diagnosed with invasive malignancy within 3 years of enrollment - Have had a blood-based multi-cancer screening test within last year - Individuals with evidence of symptomatic or active cancer requiring active therapeutic intervention at the time of participation (hormone therapy for breast/prostate cancer is considered acceptable and will not preclude participation) - Individuals in process of being evaluated for clinical suspicion of cancer - Individuals who have undergone a cancer risk-reducing surgery for hereditary cancer risk (e.g., mastectomy). - Individuals with known hematologic precursor disease (e.g. CHIP, MGUS, etc.) - Individuals without English-language proficiency

Study Design


Related Conditions & MeSH terms


Intervention

Other:
GRAIL Galleri Test
A multi-cancer early detection (MCED) blood test.

Locations

Country Name City State
United States Dana-Farber Cancer Institute Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Dana-Farber Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cancer Detection Rate Descriptive statistics will be used to summarize the number and types of cancers diagnosed by GRAIL Galleri MCED testing. Up to 2 years
Secondary Stage of Invasive Cancer Diagnosis Descriptive statistics will be used to summarize the stages of invasive cancer that are diagnosed by GRAIL Galleri MCED testing and assessed by medical record review. Up to 2 years
Secondary Positive Predictive Value At 12 Months Positive Predictive Value is defined as the proportion of participants with cancer diagnosis out of all participants with "signal detected" on GRAIL Galleri MCED test results. At 12 months
Secondary Positive Predictive Value at 24 Months Positive Predictive Value is defined as the proportion of participants with cancer diagnosis out of all participants with "signal detected" on GRAIL Galleri MCED test results. At 24 months
Secondary Time to Diagnostic Resolution Defined as the time required to achieve diagnostic resolution following a "signal detected" GRAIL Galleri MCED test result. Calculated from the date of return of screening results (up to 4 weeks from baseline) until up to 24 months post screening
Secondary Test Type Utilization to Diagnostic Resolution Per participant the count of the number and types of diagnostic tests required to achieve diagnostic resolution following a "signal detected" GRAIL Galleri MCED test result. Up to 24 months
Secondary Change in Participant Anxiety Changes in anxiety following the GRAIL Galleri MCED test result and assessed by the Patient-Reported Outcome Measurement Information System (PROMIS) Emotional Distress Anxiety - Short Form 6a, which is a 6 item survey that is rated on a 5-point Likert scale with answers ranging from "Never" to "Always". The range of scoring is from 6 to 30 with higher scores indicating greater severity of anxiety. Up to 24 months
Secondary Change in Participant Health-related Quality of Life Changes in health-related quality of life following the GRAIL Galleri MCED test result and assessed by PROMIS Scale v1.2 - Global Health, a 10 item survey that is rated on a 5-point Likert scale with answers ranging from "Excellent/Completely/Never/None" to "Poor/Not at all/Always/Very Severe" and includes a pain average question rated on a scale of 0 "No Pain" to 10 "Worst Pain Imaginable." The range of scoring is from 9 to 45 with higher scores indicating higher quality of life. Up to 24 months
Secondary Cost of Follow-up Testing Defined as the dollar cost, per participant, of follow-up testing to achieve diagnostic resolution following a "signal detected" GRAIL Galleri MCED test result. Up to 24 months
Secondary Institutional Reimbursement of Follow-up Testing Defined as the dollar cost, per participant, of the institutional reimbursement of follow-up testing to achieve diagnostic resolution following a "signal detected" GRAIL Galleri MCED test result. Up to 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT03472807 - EXOme Rare Cancers in Children (EXOCARE) N/A
Completed NCT04848142 - Psychosocial Impact of Disclosing Cancer Predisposition Genetic Testing Results During Childhood
Completed NCT03982446 - Germline Mutations in Pancreatic Adenocarcinoma
Enrolling by invitation NCT04419896 - The Informed Genetics Annotated Patient Registry